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Background: Clinical studies indicate that patients with post-traumatic stress disorder (PTSD) frequently share
comorbidity with numerous chronic pain conditions. However, the sustained effects of PTSD-like stress over time on
visceral nociception and hyperalgesia have been rarely studied, and the underlying mechanisms of stress-induced
modulation of visceral hyperalgesia remain elusive. The purpose of this study was to investigate the characterization
of visceral nociception and hyperalgesia over time in rats exposed to PTSD-like stress, and to explore the potential
role of protein kinase C gamma (PKCγ) in mediating visceral hyperalgesia following exposure to PTSD-like stress.
Results: On day 1, the rats exposed to single-prolonged stress (SPS, an established animal model for PTSD)
exhibited an analgesic response and its visceromotor response (VMR) to graded colorectal distention (CRD) at 40
and 60 mmHg was reduced compared with the control group (all P < 0.05). On day 6, the VMR returned to the
baseline value. However, as early as 7 days after SPS, VMR dramatically increased compared with its baseline value
and that in the controls (all P < 0.001) and this increase persisted for 28 days, with the peak on day 9. Abdominal
withdrawal reflex (AWR) scores were higher in SPS rats than in controls on days 7, 9, 14, 21 and 28 (all P < 0.001).
Intrathecal administration of GF109203X (an inhibitor of PKC gamma), attenuated the SPS-induced increase in both
VMR and AWR scores on days 7, 14, 21 and 28 (all P < 0.05). PKCγ protein expression determined by
immunofluorescence was reduced in the spinal cord within 3 days after the exposure to SPS (P < 0.01), which
returned to normal levels between days 4 and 6, and significantly increased from day 7, and this increase was
maintained on days 14, 21, and 28 (all P < 0.001), with the peak on day 9. In addition, Western blotting showed a
consistent trend in the changes of PKCγ protein expression.
Conclusions: The modified SPS alters visceral sensitivity to CRD, and contributes to the maintenance of visceral
hyperalgesia, which is associated with enhanced PKCγ expression in the spinal cord. Functional blockade of the
PKCγ receptors attenuates SPS-induced visceral hyperalgesia. Thus, the present study identifies a specific molecular
mechanism for visceral hyperalgesia which may pave the way for novel therapeutic strategies for PTSD-like
conditions.
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Post-traumatic stress disorder (PTSD) is a group of sym-
ptoms that occur in individuals who have been exposed
to life-threatening stressors [1-3]. Epidemiological stud-
ies have implicated PTSD-like stress as a trigger of first
onset or exacerbation or relapse of symptoms of irritable
bowel syndrome (IBS), characterized by hyperalgesia and
allodynia [4,5]. Despite the high comorbidity of chronic
pain conditions in PTSD patients [6-11], the sustained ef-
fects of PTSD-like stress over time on visceral nociception
and hyperalgesia have been rarely studied. Furthermore, the
molecular mechanisms underlying stress-induced modula-
tion of visceral pain and prolonged visceral hyperalgesia
remain unknown. Moreover, limited data on visceral pain
processing in this disorder show inconsistent results
[9,12,13], highlighting the need for further investigation.
Previous studies on PTSD have focused predominantly on
the amygdala, medial prefrontal cortex, hippocampus and
anterior cingulate of the brain [14-16]. However, there is a
growing appreciation that the dorsal horn neurons of the
spinal cord are also impacted by the stress, which can last
for weeks [17,18]. Thus, spinal sensitization is increasingly
accepted as an important component in the maintenance of
allodynia and hyperalgesia in various models of chronic
pain and stress-induced visceral hypersensitivity [19-22].
The single-prolonged stress (SPS) model, an established
animal model for PTSD, mimics some of the physiological
and behavioral changes described in PTSD patients, and
has been used to examine the therapeutic responses in vis-
ceral pain related to the intense stress [9,12,23,24].
The gamma isoform of protein kinase C (PKCγ) is
widely distributed throughout the nervous system, par-
ticularly in the interneurons of the inner part of lamina
II of the dorsal horn, which implies that PKCγ may play
a critical role in the nociceptive signaling process [25].
Accordingly, a variety of approaches have been explored
to elucidate the potential role of PKCγ as a pain me-
diator in nociceptive signal transduction [26-29]. It has
been demonstrated that PKCγ is involved in many as-
pects of cellular sensitization, including modulation of
channel conductivity, increased trafficking of receptors,
and release of excitatory neurotransmitters [30]. PKCγ
plays an important role in the sensitization of nocicep-
tive neurons of dorsal horn in certain pain states and
thus algesic hypersensitivity in several animal models of
visceral pain and visceral injury [9,16,30-32]. PKCγ ex-
pression is upregulated under pain conditions resulting
from nerve damage or inflammation in animal models
[26-29], indicating its involvement in both neuropathic
and inflammatory pain. Lower mechanical and thermal
hyperalgesia has been observed in PKCγ knock-out mice
in response to nerve damage [26,30,33], and spinal block-
ade of PKCγ reverses the hyperalgesia induced by sub-
cutaneous formalin, pancreatitis and cutaneous capsaicin[34-37]. Although all these data support a role for PKCγ
in visceral pain, it is unknown whether PKCγ also contrib-
utes to the maintenance of chronic visceral hyperalgesia
over time following exposure to PTSD-like stress. We
postulate that PKCγ is the potential mechanism through
which spinal sensitization may occur in response to
PTSD-like stress.
Therefore, the purpose of this study was to investigate
the characterization of visceral nociception and hyperalge-
sia over time in rats exposed to PTSD-like stress, and to
explore the potential role of PKCγ in mediating visceral
hyperalgesia following exposure to PTSD-like stress. This
study showed that SPS altered visceromotor response
(VMR) and abdominal withdrawal reflex (AWR) to graded
colorectal distention (CRD) and contributed to the devel-
opment of delayed visceral hyperalgesia, which is accom-
panied by PKCγ overexpression. GF109203X (an inhibitor
of PKCγ) attenuated the VMR and AWR in SPS-exposed
rats. Thus, the present study provides direct evidence for
the role of PKCγ in SPS-induced visceral hyperalgesia,
and may pave the way for novel therapeutic strategies for
PTSD-like stress.Results
Alteration of VMR to graded CRD over time following
exposure to SPS
VMR to CRD was recorded at different time points
(baseline, days 1, 6, 7, 10, 14, 21, 28 and 29) after SPS
exposure. The baseline VMR to CRD was equivalent
between control and pre-SPS groups in a pressure-
dependent manner (Figure 1). However, on day 1, SPS-
treated rats exhibited an analgesic response, and the
VMR to CRD was reduced at both 40 and 60 mmHg
compared with control rats (0.301 ± 0.012 vs. 0.380 ±
0.014, P = 0.013 and 0.417 ± 0.018 vs. 0.535 ± 0.020, P <
0.001, respectively). On day 6, the VMR returned to the
baseline values in SPS rats. However, on day 7, the VMR
to CRD was significantly increased at both 40 and
60 mmHg, and the mean area under the curve (AUC) of
electromyographic (EMG) signal in SPS rats was signifi-
cantly increased compared with its baseline value and
that in the controls (all P < 0.001). There was a signifi-
cant increase in the VMR to graded intensities of phasic
CRD (40 and 60 mmHg) between day 7 and day 28 com-
pared with baseline value in SPS rats and those in the
control rats (all P < 0.001), with the peak on day 9 after
SPS exposure. On day 29, the VMR decreased to a level
similar to baseline levels (Table 1).
At a distension pressure of 60 mmHg, 87% of the
SPS-exposed rats developed an increased VMR 7 days
following exposure to SPS; 22%, 38% and 27% exhibited
an increase in VMR by 1–50%, 51–100%, and > 101%
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Figure 1 Baseline visceromotor response to graded colorectal distension in the control rats and those to be exposed to single-prolonged
stress Pre-(SPS).
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exposure to SPS
Visceral pain sensitivity was also determined by measuring
the AWR scores in response to graded CRD (10, 20, 40
and 60 mmHg) at various time points (baseline, days 1, 6,
7, 14, 21, 28 and 29 after SPS). The AWR scores were
higher in rats exposed to SPS at 40 and 60 mmHg than in
control rats on days 7, 9, 14, 21 and 28 (all P < 0.001)
(Table 2).
Effects of GF109023X on VMR to CRD following exposure
to SPS
Since the peaking VMR to phasic CRD (40 and 60 mm
Hg) was on day 9 after exposure to SPS, we chose this
time point to investigate the dose–response effects of
GF109023X at doses of 0.05-0.50 nmol/10 μL on VMR to
CRD, and determined the effective dose that completelyTable 1 Visceromotor response (VMR) to phasic ascending co
single-prolonged stress
Group 10 mm Hg 20 mm
Control (n = 8) 0.055 ± 0.006 0.259 ±
Post-1 day (n = 7) 0.053 ± 0.007 0.230 ±
Post-6 days (n = 8) 0.047 ± 0.006 0.263 ±
Post-7 days (n = 10) 0.056 ± 0.006 0.284 ±
Post-9 days (n = 7) 0.059 ± 0.007 0.329 ±
Post-14 days (n = 8) 0.048 ± 0.005 0.254 ±
Post-21 days (n = 10) 0.053 ± 0.006 0.291 ±
Post-28 days ( n = 9) 0.050 ± 0.005 0.312 ±
Post-29 days (n = 9) 0.042 ± 0.003 0.291 ±
All data are expressed as the mean ± S.E.M.
VMR was represented by the mean value of the area under the curve of the electro
* P < 0.05 compared with Control.
▲ P < 0.001 compared with Control.
∇ P < 0.05 compared with post-29 days.inhibits the response to 60 mmHg CRD, a noxious inten-
sity. When administered intrathecally, GF109203X at low
doses ranging from 0.05-0.15 nmol/10 μL did not signifi-
cantly affect VMR to the graded intensities of phasic CRD.
However, at 0.30 nmol/10 μL, GF109023X significantly atten-
uatedVMR toCRD at 40mmHg in the SPS-treated rats com-
pared with the vehicle group (0.584 ± 0.032 vs. 0.670 ± 0.028,
P = 0.013); no such effect was observed at 60 mmHg. At
0.50 nmol/10 μL, GF109023X completely inhibited the re-
sponse to CRD at both 40 mmHg (0.541 ± 0.014 vs. 0.670 ±
0.028, P < 0.001) and 60 mmHg (0.681 ± 0.018 vs. 0.896 ±
0.008, P < 0.001) in SPS-treated rats compared with the ve-
hicle group and with the low-dose groups (all P < 0.001) (Fig-
ures 2A& 2B,Table 3).
In addition, intrathecal administration of 0.50 nmol/
10 μL of GF109203X 10 min before CRD abolished vis-
ceral hyperalgesia and attenuated SPS-induced increase inlorectal distention (CRD) over time following exposure to
Hg 40 mm Hg 60 mm Hg
0.013 0.380 ± 0.014 0.535 ± 0.020
0.012 0.301 ± 0.012*∇ 0.417 ± 0.018*∇
0.019 0.359 ± 0.012 0.536 ± 0.022
0.020 0.617 ± 0.022▲∇ 0.759 ± 0.022▲∇
0.015 0.670 ± 0.028▲∇ 0.896 ± 0.008▲∇
0.037 0.653 ± 0.020▲∇ 0.818 ± 0.020▲∇
0.017 0.648 ± 0.021▲∇ 0.823 ± 0.017▲∇
0.016 0.623 ± 0.024▲∇ 0.839 ± 0.026▲∇
0.021 0.450 ± 0.022 0.594 ± 0.025
myographic activity during CRD.
Table 2 Abdominal withdrawal reflex score in response to phasic ascending colorectal distention over time following
exposure to single-prolonged stress
Group 10 mm Hg 20 mm Hg 40 mm Hg 60 mm Hg
Control (n = 8) 1.099 ± 0.120 2.050 ± 0.109 2.586 ± 0.134▲ 2.850 ± 0.132▲
Post-1 day (n = 7) 1.117 ± 0.159 2.029 ± 0.157 1.942 ± 0.149*& 1.986 ± 0.122*&
Post-6 days (n = 8) 1.170 ± 0.113 2.050 ± 0.109 3.125 ± 0.096*▲& 3.625 ± 0.206*▲&
Post-7 days (n = 10) 1.067 ± 0.072 2.090 ± 0.067 3.190 ± 0.057*▲& 3.860 ± 0.134*▲&
Post-9 days (n = 7) 1.043 ± 0.100 2.100 ± 0.079 3.186 ± 0.083*▲& 3.871 ± 0.161*▲&
Post-14 days (n = 8) 1.100 ± 0.101 2.050 ± 0.065 3.162 ± 0.065*▲& 3.650 ± 0.093*▲&
Post-21 days (n = 10) 1.109 ± 0.081 2.040 ± 0.056 3.170 ± 0.063*▲& 3.800 ± 0.089*▲&
Post-28 days ( n = 9) 1.078 ± 0.101 2.022 ± 0.061 3.222 ± 0.055*▲& 3.522 ± 0.072*▲&
Post-29 days (n = 9) 1.080 ± 0.085 2.000 ± 0.058 2.638 ± 0.091▲ 2.800 ± 0.097▲
All data are expressed as the mean ± S.E.M.
* P < 0.001 compared with Control.
▲ P < 0.001 compared with post-1 day.
& P < 0.001 compared with post-29 days.
He et al. Molecular Pain 2013, 9:35 Page 4 of 14
http://www.molecularpain.com/content/9/1/35VMR to CRD at 40 and 60 mmHg on days 7, 14, 21 and
28 after SPS, when compared with vehicle injection (all
P < 0.05) (Figures 3A & 3B). In control rats, GF109203X
had no significant effects on the VMR to CRD.
Effects of GF109023X on AWR to CRD following
exposure to SPS
We also investigated the dose–response effects of
GF109023X on AWR to CRD on day 9 after expo-
sure to SPS. At low-doses (0.05-0.15 nmol/10 μL),
GF109203X had no significant effects on AWR to the
graded intensities of phasic CRD. However, at 0.30 nmol/
10 μL, GF109023X significantly attenuated the AWR to
CRD at 40 mmHg in SPS-treated rats compared with the
vehicle group (2.825 ± 0.103 vs. 3.186 ± 0.083, P = 0.017);
no such effect was observed at 60 mmHg. At 0.50 nmol/
10 μL, GF109023X completely attenuated the AWR in re-
sponse to CRD at both 40 and 60 mmHg, with the AWR
scores to CRD being significant decreased in SPS-treated
rats when compared with the vehicle group (2.744 ± 0.100
vs. 3.186 ± 0.083, P = 0.003 for 40 mmHg and 3.011 ± 0.353
vs. 3.871 ± 0.161, P = 0.005 for 60 mmHg), and with the
low-dose groups (all P < 0.05) (Table 4 and Figures 4A &
4B).
In addition, the administration of GF109203X at
0.50 nmol/10 μL caused a significant reduction of AWR
to CRD at 40 and 60 mmHg on days 7, 14, 21 and 28
compared with baseline and vehicle injection (all P <
0.05) (Figures 5A & 5B). In control rats, GF109203X had
no significant effects on the AWR to CRD.
Spinal PKCγ protein expression over time following
exposure to SPS as determined by immunofluorescence
staining
In the dorsal horn of the spinal cord, PKCγ immuno-
staining formed a dense plexus, consisting of stronglyimmunoreactive cell bodies and associated dendrites.
The most strongly PKCγ-immunoreactive neurons were
located in the inner plexus of lamina II (Iii) and ventral
to the plexus in lamina III, whereas weakly stained cells
were present in the outer part of lamina II (IIo) and in
lamina I. By immunofluorescence analysis, SPS-treated
rats exhibited a reduced PKCγ expression in the dorsal
horn of the spinal cord within 3 days after exposure to
SPS compared with baseline (P < 0.01, Figures 6A & 6B);
however, those neuronal stores were replenished be-
tween days 4 and 6 after exposure to SPS. SPS signifi-
cantly increased PKCγ expression in the dorsal horn of
the spinal cord as early as on day 7, compared with the
control rats, with the average optical density (AOD) of
immunoreactivity being 143.44 ± 2.40 vs. 108.50 ± 3.66,
P < 0.001 (Figure 6C). This increase was maintained on
days 14 (148.22 ± 4.02), 21 (147.33 ± 3.77), and 28
(149.11 ± 4.68) in SPS-treated rats compared with the
control rats (all P < 0.001) (Figures 6D-F, Table 5). A
similar trend was noted on day 29 after SPS, but this
was not statistically significant (P = 0.420). The peak ex-
pression of PKCγ was reached on day 9 (Figure 6G). In
the meantime, there was no marked difference in the
PKCγ expression in the SPS exposed rats among differ-
ent time points (all P > 0.05). Negative controls (treated
without the primary antibody) had no staining.
Spinal PKCγ protein expression over time following
exposure to SPS as determined by Western blotting
The PKCγ protein expression was analyzed with Western
blotting from the spinal cord homogenates. On day 1,
the relative optical density (ROD) of the PKCγ immuno-
blot bands in the spinal cord was significantly decreased
in SPS-exposed rats, compared with the control rats
(P < 0.001). PKCγ expression was significantly increased
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Figure 2 Effect of GF109203X (GF) at different doses on visceromotor response to phasic colorectal distention at 40 mmHg (A) and
60 mmHg (B) 9 days following exposure to single-prolonged stress (SPS). All data are expressed as the mean ± S.E.M. * P < 0.05, and
** P < 0.001, compared with SPS + Vehicle, respectively; & P < 0.001, compared with SPS + Vehicle; # P < 0.001, compared with SPS + GF (0.5 nmol).
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compared with the controls (all P < 0.001) (Figure 7 and
Table 6).
Discussion
Clinical studies indicate that PTSD patients frequently
shares comorbidity with numerous chronic pain conditions.
However, only a few studies have examined if subjection toTable 3 Effect of GF109203X (GF) on visceromotor response t
following exposure to single-prolonged stress (SPS)
Group 10 mm Hg 2
Control (n = 8) 0.055 ± 0.006 0.2
SPS + Vehicle (n = 7) 0.059 ± 0.007 0.2
SPS + GF (0.05 nmol) (n = 7) 0.059 ± 0.004 0.2
SPS + GF (0.15 nmol) (n = 8) 0.059 ± 0.004 0.2
SPS + GF (0.30 nmol) (n = 8) 0.054 ± 0.004 0.2
SPS + GF (0.50 nmol) (n = 9) 0.053 ± 0.003 0.2
All data are expressed as the mean ± S.E.M.
* P < 0.05, and ** P < 0.001, compared with SPS + Vehicle, respectively.
$ P < 0.001, compared with SPS + Vehicle.
# P < 0.001, compared with SPS + GF (0.50 nmol).PTSD-like conditions alters visceral nociception and
hyperalgesia, which reported decreased or unchanged
nociceptive sensitivity [8,9,11]. In addition, the molecular
mechanisms underlying stress-induced modulation of vis-
ceral hyperalgesia remain elusive. PKCγ as a pain marker
has been shown to be important in several animal models
of visceral pain, and is thought to play a role in long term
hyper-excitability or sensitization in nociceptive neuronso phasic ascending colorectal distention over time
0 mm Hg 40 mm Hg 60 mm Hg
59 ± 0.013 0.380 ± 0.014$ 0.535 ± 0.020$
99 ± 0.013 0.670 ± 0.028# 0.896 ± 0.008#
93 ± 0.021 0.676 ± 0.012# 0.874 ± 0.010#
81 ± 0.017 0.666 ± 0.031# 0.874 ± 0.014#
78 ± 0.019 0.584 ± 0.032* 0.856 ± 0.015#
















































P = 0.015 P = 0.002 P = 0.007
B
Figure 3 Effect of GF109203X (GF) at 0.5 nmol/10 μL on visceromotor response to phasic colorectal distention at 40 mmHg (A) and
60 mmHg (B) following exposure to single-prolonged stress (SPS). All data are expressed as the mean ± S.E.M. (n = 7–10). All P < 0.05,
compared with the Vehicle group.
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pothesized that PTSD-like stress alters visceral sensitivity
and produces visceral hyperalgesia, and spinal activation
of PKCγ mediates the development of persistent visceral
hyperalgesia following exposure to PTSD-like stress.
Therefore, we examined the characterization of visceralTable 4 Effect of GF109203X (GF) on abdominal withdrawal r
distention over time following exposure to single-prolonged
Group 10 mm Hg 20
Control (n = 8) 1.099 ± 0.120 2.0
SPS + Vehicle (n = 7) 1.043 ± 0.010 2.1
SPS + GF (0.05 nmol) (n = 7) 1.153 ± 0.098 2.0
SPS + GF (0.15 nmol) (n = 8) 1.030 ± 0.065 2.0
SPS + GF (0.30 nmol) (n = 8) 1.120 ± 0.087 2.0
SPS + GF (0.50 nmol) (n = 9) 1.060 ± 0.064 1.9
All data are expressed as the mean ± S.E.M.
* P < 0.05, and ** P < 0.01, compared with SPS + Vehicle, respectively.
# P < 0.05, compared with SPS + GF (0.50 nmol).
& P < 0.01, compared with SPS + Vehicle.nociception and hyperalgesia over time following exposure
to PTSD-like stress, and explored the role of PKCγ signal-
ing in the development of stress-induced visceral hyper-
algesia at the spinal level and provided novel insights into
its underlying molecular mechanisms of stress-related
pain modulation.eflex score in response to phasic ascending colorectal
stress (SPS)
mm Hg 40 mm Hg 60 mm Hg
50 ± 0.109 2.588 ± 0.134& 2.850 ± 0.132&
00 ± 0.079 3.186 ± 0.083 3.871 ± 0.161
71 ± 0.102 3.229 ± 0.068# 3.700 ± 0.115#
88 ± 0.048 3.125 ± 0.084# 3.575 ± 0.139#
38 ± 0.080 2.825 ± 0.103* 3.700 ± 0.118#
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Figure 4 Effect of GF109203X (GF) at different doses on abdominal withdrawal reflex score in response to phasic colorectal distention
at 40 mmHg (A) and 60 mmHg (B) following exposure to single-prolonged stress (SPS). All data are expressed as the mean ± S.E.M.
* P < 0.05, and ** P < 0.01, compared with SPS + Vehicle; # P < 0.05, compared with SPS + GF (0.5 nmol); & P < 0.01, compared with SPS + Vehicle.
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of modified SPS, an established animal model for PTSD
[23,24]. The inescapable electric foot shock, which is often
employed to produce fear or anxiety and considered a noci-
ceptive stimulus, was added to the conventional SPS proce-
dures, and reported to significantly enhance conditioned
and sensitize fear responses [24]. This model mimics some
of the physiological, behavioral changes, hypothetical
pathogenesis and clinical pain features described in PTSD
patients that includes enhanced negative feedback to the
hypothalamic-pituitary-adrenal axis, anxiety-like behavior,
cognitive impairments and memory dysfunction [23,24,38].
This model is also responsive to treatments showing some
efficacy in alleviating visceral pain in IBS patients and there-
fore can predict treatment responses to specific drugs or
nonpharmacological interventions in humans [9,12].
Previous animal studies have demonstrated that acute
and chronic stress is associated with the development of
allodynia, hyperalgesia or unaltered nociceptive sensitiv-
ity [17,18,39,40]. For example, 10–20 min forced swim-
ming daily for 3 days induces hyperalgesia to thermal
and chemical stimuli 8 to 9 days after the last swim ses-
sion [17]. Exposure to water avoidance stress (WAS) for
1 h leads to a delayed visceral hyperalgesia to CRD,appearing 24 h after the end of the stress, and 10-day
homotypic water avoidance stress induces visceral hyper-
sensitivity that lasts for about 40 days [18]. Interestingly,
exposure to a stressor stronger than WAS was found to
induce an immediate hyperalgesia to CRD [41]. More-
over, the stress-related experimental models of IBS have
demonstrated a lowered pain threshold and hyperalgesia
to CRD [12,18,42-44]. In addition, female rats appear to
show a different pattern of sensitized behavioral respon-
siveness to the same challenge, indicating sex-related
alterations in the neuronal substrates involved in the re-
sponsiveness [12,41,44].
The present study demonstrated that there was a sig-
nificant effect of SPS on VMR and AWR to distention,
indicating that changes in visceral nociception and
hyperalgesia differed over time between control and SPS
rats. SPS-treated rats exhibited a temporary visceral an-
algesia within the initial 3 days following SPS exposure.
Then, it was replenished on days 4 and 5, and returned to
the baseline on day 6. SPS-induced analgesia on day 1 may
be mediated by activation of the descending inhibitory pain
pathway [45-47]. Pharmacological and neurochemical stud-
ies have demonstrated involvement of a large number of


























































P = 0.025 P = 0.014 P = 0.019
P = 0.046
B
Figure 5 Effect of GF109203X (GF) at 0.5 nmol/10 μL on abdominal withdrawal reflex score in response to phasic colorectal distention
at 40 mmHg (A) and 60 mmHg (B) following exposure to single-prolonged stress (SPS). All data are expressed as the mean ± S.E.M.
(n = 7–10). All P < 0.05, compared with the Vehicle group.
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glutamate systems [45-47]. In addition, the present study
showed down-regulation of PKCγ on day 1 after SPS, which
may be another potential mechanism for stress-induced an-
algesia. These findings may enhance our understanding of
the fundamental pathophysiology of SPS-induced visceral
analgesia; however, further studies are required to deter-
mine whether the PKCγ signaling pathway can be a new
therapeutic target for the treatment of stress-related func-
tional gastrointestinal disorders.
In the present study, both VMR and AWR to CRD dra-
matically increased 7 days after initiation of SPS and the
increased nociceptive responses were maintained for up to
28 days. However, visceral sensitivity did not differ within
the control group over the 28 day period, indicating that
the rats did not become sensitized to repeated CRD as-
sessments over time. The development of the peripheral
and central sensitization may be important in mediating
stress-induced visceral hypersensitivity to CRD, in which
maladaptive neuroplastic changes lead to persistently
increased perception and response to noxious, or non-noxious stimuli [9,48,49]. Moreover, it has been reported
that once peripheral and central sensitization has devel-
oped, it can in turn activate the release of spinal cordmedia-
tors such as acid-sensing ion channel 1a, neurokinin-1, and
growth factors such as nerve growth factor or brain-derived
neurotrophic factor and phosphorylation of extracellular
signal-regulated kinases 1 and 2 (ERK1/2) as a result of
stress exposure [22,50-52]. In the present study, PKCγ was
up-regulated on days 7, 14, 21 and 28 after SPS in the spinal
cord, indicating that it may also mediate the development
of visceral hyperalgesia. Such alterations in the processing
of visceral nociception are all considered as possiblemecha-
nisms of chronic visceral hyperalgesia following exposure
to PTSD-like conditions.
The present study demonstrated that, concurrent with
sustained visceral hyperalgesia, PKCγ protein expression
in the dorsal horn neurons of the spinal cord was
dramatically increased as early as 7 days after initiation
of SPS and sustained for at least another three weeks.
This finding indicates that PKCγ protein expression is
consistently upregulated and thus PKCγ in the spinal
Figure 6 PKCγ protein expression by immunofluorescence in the spinal level over time following exposure to single-prolonged stress.
Representatives illustrating the distribution of PKCγ-immunoreactivity (IR) in the dorsal horn of control rats (A), and those day 1 (B), 7 (C), 14 (D)
21 (E), 28 (F), 9 (G) after exposure to SPS.
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neuronal activity in algesic and nociceptive signaling
pathways. It is conceivable that PKCγ release and bio-
synthesis are accelerated following exposure to PTSD-
like conditions, and the activation of PKCγ may produce
an increased visceral nociceptive sensitivity. Although
whether elevated PKCγ is a cause of the increased vis-
ceral nociceptive sensitivity needs further investigation,
increased PKCγ expression at 28 day after initiation of
SPS may reflect the broad spectrum of its roles in thedevelopment and maintenance of visceral hyperalgesia
during PTSD. It is also implied the activation of PKCγ
receptors contributes to the development of visceral
pain hypersensitivity and hyperalgesia following expos-
ure to PTSD-like stress. Therefore, the present study
adds PKCγ to the list of key nociceptive molecules that
participate in hypersensitivity in this model and under-
scores the fact that such visceral sensitization is accom-
panied by long lasting plasticity of sensory neurons in a
PTSD-like stress state.
Table 5 Average optical density of PKCγ
immunofluorescence in the dorsal horn of the spinal cord
of rats following exposure to single-prolonged stress
Group AOD values
Control (n = 8) 108.50 ± 3.66
Post-1 day (n = 7) 90.57 ± 2.83*
Post-6 days (n = 7) 102.57 ± 3.21∇
Post-7 days (n = 9) 143.44 ± 2.40**▲&
Post-9 days (n = 8) 153.50 ± 3.13**▲&
Post-14 days (n = 9) 148.22 ± 4.02**▲&
Post-21 days (n = 9) 147.33 ± 3.77**▲&
Post-28 days (n = 9) 149.11 ± 4.68**▲&
Post-29 days (n = 8) 104.25 ± 3.97∇
All data are expressed as the mean ± S.E.M.
*P < 0.01 and **P < 0.001, compared with control group, respectively.
▲ P < 0.001 compared with post-1 days group.
∇ P < 0.05 compared with post-1 days group.
& P < 0.05 compared with post-29 days group.
Table 6 Relative optical density of PKCγ protein
expression in the spinal cord of rats following exposure
to single-prolonged stress as determined by Western
blotting
Group ROD
Control (n = 7) 1.000 ± 0.000▲
Post-1 day (n = 7) 0.774 ± 0.024*&
Post-6 days (n = 6) 0.975 ± 0.028▲
Post-7 days (n = 8) 1.284 ± 0.025*▲&
Post-9 days (n = 7) 1.376 ± 0.021*▲&
Post-14 days (n = 8) 1.345 ± 0.027*▲&
Post-21 days (n = 7) 1.351 ± 0.027*▲&
Post-28 days (n = 8) 1.316 ± 0.023*▲&
Post-29 days (n = 7) 0.990 ± 0.019▲
All data are expressed as the mean ± S.E.M.
* P < 0.001 compared with control group.
▲ P < 0.001 compared with post-1 days group.
& P < 0.001 compared with post-29 days group.
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PKCγ inhibitor, at 0.5 nmol/10 μL, a dose several fold
higher than the ED50 [30], achieved a significant attenu-
ation of muscle-induced mechanical hyperalgesia. In the
present study, visceral nociceptive responses to CRD
following exposure to PTSD-like stress was blocked by
GF109203X at the spinal level, suggesting that PKCγ
inhibitors may be neuroprotective in disorders with
dysregulated PKCγ signaling following PTSD-like stress,
and thus, supporting that spinal PKCγ activation plays a
functional role in the development of visceral hypersensi-
tivity, and enhanced responsiveness after SPS exposure is
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There are several possibilities that could explain how
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several injury-activated pathways [53-55]. Second, spinal
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rons, increases release of glutamate in the spinal cord, and
sensitizes the spinothalamic tract and other dorsal horn
neurons, and formalin-induced release of glutamate is
prevented by blockade of PKCγ [30,55-57]. Thus, PKCγ
produces increased release of glutamate resulting in contin-
ued activation of glutamate receptors. Furthermore, spinal
activation of PKCγ enhances responses of dorsal horn neu-
rons to N-methyl-D-aspartate (NMDA) and alpha-amino-
3-hydroxy-5-methylisoxazole-4-propionic acid agonists,
which are involved in NMDA receptor-mediated mecha-
nisms of visceral hyperalgesia. Also, spinal activation of
PKCγ increases phosphorylation of the NMDA receptor
subunit, NR1, and glutamate receptor subunit, GlurR1,
which could result in an increased channel conductance
and increase number of its receptors available in the mem-
brane synaptically, resulting in increased excitation of the
nociceptive spinal neurons [58-60]. Third, PKCγ decreases
the effects of inhibitory neurotransmitters on spinotha-
lamic tract neurons, which is manifested as an increased
excitation and the increased PKCγ activity reduces normal
inhibition within the spinal cord [61,62]. Therefore, this
would result in increased excitability of neurons that is
manifested as increased VMR and AWR scores to noxious
stimuli.
Conclusions
The present study indicates that SPS alters visceral sen-
sitivity to CRD, and contributes to the development and
maintenance of delayed visceral hyperalgesia, which is
associated with an enhanced PKCγ expression in the
dorsal horn of the spinal cord. Functional blockade of
PKCγ receptors attenuates SPS- induced visceral hyper-
algesia. These data indicate that the large enhancement
of PKCγ expression and function may contribute to the
development and maintenance of visceral hyperalgesia.
The present study provides direct evidence for a role of
PKCγ in SPS- induced visceral pain, and thus may iden-
tify a specific molecular mechanism for visceral hyper-
algesia which may pave the way for novel therapeutic
strategies for PTSD-like conditions.
Methods
Animals
Experiments were performed on 8-week-old female
Sprague–Dawley rats (220–300 g). The animals were
housed under controlled conditions (21-25°C, 12/12 h
light/dark cycle) with availability to standard rat chow
and water ad libitum. Prior to the experiments, the ani-
mals were fasted for 18–24 h with free access to water.
The study protocol with care and handling of these an-
imals was approved by the Institutional Animal Care
and Use Committee at the Third Military Medical Uni-
versity. Experiments were performed were in accordancewith the Guidelines of the International Association for
the Study of Pain. Animals were allowed to acclimate for
at least 7 days before experiments.
Intrathecal catheter implantation
Each of the rats was implanted with a chronic indwelling
intrathecal catheter for drug or vehicle delivery. Briefly,
animals were placed under general anesthesia using
isoflurane inhalation (3.0%). A 23 G needle was inserted
into the intrathecal space between L5 and L6 until a tail
flick was elicited confirming intrathecal placement. A
catheter was considered correctly placed if there was loss
of sensory and motor function after injection of lido-
caine. A gentamicin sulfate-flushed polyethylene (PE-10)
tube was then inserted 4 cm deep so the tip was located
for spinal lumbar enlargement. Once the catheter was
secured to the fascia, the PE-10 tube was threaded out
between the shoulder blades, and the incision was closed
with wound clips. Rats were not tested for at least 7 days
after surgery. Animals demonstrating motor dysfunction
or dehydration immediately following surgery or at any
point thereafter were euthanized.
Drug administration
Drugs were administered to the animals through the intra-
thecal catheter. A 30 G drug delivery needle attached to a
PE-50 tube was affixed to the end of a 50 μL syringe.
Drugs were delivered as a 10 μl bolus. For the behavioral
experiment, GF109203X (Calbiochem, San Diego, CA), a
specific PKC inhibitor, was dissolved in 10% dimethyl sulf-
oxide (DMSO). Then, GF109203X at different concentra-
tions (0.05-0.50 nmol/10 μL) or vehicle (DMSO) was
injected within 2 min directly into the lumbar spinal cord
via the indwelling intrathecal catheter, and 10 min later,
the number of AWR and EMG responses to CRD was
measured as described below. SPS exposed rats were
treated with one of four different doses of GF109203X
alone (0.05, 0.15, 0.30 and 0.50 nmol/10 μL), and the
dose–response effects of GF109023X were determined
and the effective dose, which was defined as the dose that
completely inhibits the response to 60 mmHg CRD, a
noxious intensity, was identified for further experiments.
Modified single-prolonged stress for post-traumatic stress
disorder
The detailed SPS procedure was performed as previously
described [23,24] with modification. Briefly, animals
were restricted in a disposable plastic holder (7 cm
diameter, 21 cm in length) for 2 h, and then individually
placed in a clear acrylic cylinder (20 cm diameter) filled
to two thirds (35 cm) of its height with water (24°C) and
forced to swim for 20 min, and following 15 min
recuperation, exposed to inhalation of anesthetic isoflurane
until the loss of consciousness. When they recovered
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4 s) was delivered via metal grids installed in the bottom of
the chamber.
Implantation of EMG electrodes
Currently, the “gold standard” for assessing visceral noci-
ceptive response is recording abdominal smooth muscle
contractions, as a proxy to the VMR to CRD in conscious
animals. In brief, rats were deeply anesthetized with so-
dium pentobarbital (45 mg/kg) administered intraperito-
neally. Electrodes (Teflon-coated stainless steel wire,
Cooner Wire, CA, USA) were stitched into the external
oblique musculature, just superior to the inguinal liga-
ment, for EMG recordings as previously described [63].
The electrode leads were then tunneled subcutaneously
and externalized laterally through the skin of the abdomen
and neck for future access. The incisions were closed with
wound clips. Wounds were tested for tenderness to ensure
complete recovery from surgery before behavioral testing
as described below.
Behavioral Testing for Nocifensive Responses
Visceromotor responses
Visceral sensitivity was measured by grading behavioral
response of rats to phasic CRD as previously described
[63-65] before initiation of SPS (on day 0, as baseline)
and at various time points (on days 1, 6, 7, 9, 14, 21, 28
and 29) in rats exposed to SPS. Briefly, after an over-
night fast, the rats were anesthetized using isoflurane in-
halation (3.0%). A flexible latex balloon (5 cm) attached
to a tygon tube was inserted 8 cm into the descending
colon and rectum via the anus and held in place by tap-
ing the tubing to the base of the tail. After the rat
regained consciousness, the rat was allowed to adapt for
30 min prior to CRD. Attachment of a strain gauge force
transducer to the abdominal oblique muscle allowed dir-
ect monitoring of the muscle contractile activity, and CRD
was performed by rapidly inflating the balloon to a constant
pressure with a pressure control device (Micro-1401, CED,
UK). The distension protocol consisted of a series of phasic
CRD to constant pressures of 10, 20, 40, and 60 mmHg,
for 20 seconds followed by a 4 min interstimulus interval
[64]. To examine the pressure-response relationship, the
EMG activity was rectified, and the increase in the AUC of
EMG amplitude (over baseline) was recorded as previously
described [65].
Abdominal withdrawal reflex
Behavioral response to CRD was also measured by visual
observation of the AWR, as previously described [13]. The
AWR were scored as follows: 0, no behavioral response to
CRD; 1, brief head movement followed by immobility; 2,
contraction of abdominal muscles; 3, lifting of abdomen;
and 4, body arching and lifting of pelvic structures. Duringtesting, the observers were completely blinded to the
training conditions.
Western blotting
Animals were anesthetized with 4% isoflurane and decapi-
tated, and the lumbosacral spinal cord segment was dis-
sected. The tissue, weighing 20 mg, was homogenized in
100 μL of lysis buffer containing 50 mM Tris–HCl pH 8.0,
150 mM NaCl, 1 mM ethylenediamine-N,N,N’,N’-tetra-
acetic acid (EDTA), 0.5% Triton X-100 and a complete
protease inhibitor. The homogenate was incubated on ice
for 30 min and then the suspension was sonicated on ice
using three 10-second bursts at high intensity with a 10-
second cooling period between each burst. The samples
were centrifuged at 13000 rpm for 15 min at 4°C and the
supernatant was collected and stored at −80°C. The pro-
tein concentrations were determined by the BCA Protein
Assay Kit as described by the manufacturer. Each protein
sample (60 μg) was loaded in 8% sodium dodecyl sulfate-
polyacrylamide gel (Bio-Rad), by electrophoresis and then
transferred to polyvynilidene fluoride membranes. The
membranes were blocked with 5% non-fat dry milk in
Tris-buffered saline with 0.5% Tween-20 (TBST) buffer at
room temperature for 1 h and incubated with the primary
antibody (PKCγ, at 1:1000, Abcam) overnight at 4°C. After
washing in TBST, the membranes were incubated with the
secondary antibody [horseradish peroxidase (HRP)-conju-
gated goat anti-rabbit IgG] in 3% milk-TBST (1:3,000
dilution) for 2 h at room temperature. After washing
with TBST three times, the HRP-antibody signal was de-
tected by the electrochemiluminescence (ECL) kit from
Amersham (GE Healthcare, Piscataway, NJ, USA), fol-
lowed by exposure to Kodak X-ray film. The membranes
were subsequently stripped and re-probed for anti-β-actin
antibody (1: 1000, Santa Cruz). Films were scanned and the
intensity of PKCγ immunoreactive bands was quantified
using Bio-Rad Quantity One software and normalized rela-
tive to the intensity of the β-actin immunoreactive band.
Immunofluorescence staining
For PKCγ immunofluorescence staining, animals were
anesthetized with sodium pentobarbital (45 mg/kg) ad-
ministered intraperitoneally and perfused transcardially
with 150 mL phosphate-buffered saline (PBS) followed by
400 mL ice-cold 4% paraformaldehyde (PFA) in phosphate
buffer (PB), pH 7.4. Spinal cords were removed and
postfixed for 4 h in PFA and transferred to 30% sucrose
overnight in PB for cryoprotection, and then cut using a
cryostat at 30 μm in thickness. The immunostainings were
performed using the ‘free floating’ technique for the spinal
cord. Briefly, the sections were blocked for 1 h in blocking
buffer (10% donkey serum) at room temperature, and then
anti-PKCγ antibody (diluted 1:1000, Abcam) was added
overnight at room temperature. After washing three times
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with the following secondary antibodies (Cy3, Invitrogen,
diluted 1:200) for 1 h at room temperature. Images were
viewed and captured using a BX50 Olympus microscope
(Center Valley, PA), using Image-Pro Plus software 6.0
(USA) to analyze the immunofluorescence staining.
Data analysis
Statistical analyses of the data were performed on the
computer using the software PASW 17.0 (Chicago, Illinois,
USA). All numerical data were expressed as the mean ±
standard error of mean (S.E.M.) and statistical significance
was determined by the student t-test or analysis of vari-
ance (ANOVA) test, followed by the least significant dif-
ference multiple comparison post hoc test. P values of less
than 0.05 were considered statistically significant.
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